148 related articles for article (PubMed ID: 17075587)
1. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Verit A
Int J Impot Res; 2006; 18(6):574; author reply 575. PubMed ID: 17075587
[No Abstract] [Full Text] [Related]
2. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
3. Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
Barqawi A; Crawford ED
Int J Impot Res; 2006; 18(4):323-8. PubMed ID: 16281043
[TBL] [Abstract][Full Text] [Related]
4. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
6. Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma?
Landau D; Tsakok T; Aylwin S; Hughes S
Clin Endocrinol (Oxf); 2012 Feb; 76(2):179-81. PubMed ID: 21951017
[TBL] [Abstract][Full Text] [Related]
7. The role of testosterone replacement therapy following radical prostatectomy.
Khera M; Lipshultz LI
Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
9. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
10. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
11. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer following testosterone replacement in Klinefelter syndrome.
Bydder SA; Joseph DJ; Weinstein S; Stuckey BG
ANZ J Surg; 2007; 77(1-2):93-4. PubMed ID: 17295832
[TBL] [Abstract][Full Text] [Related]
13. Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden EL; Morgentaler A
N Engl J Med; 2004 Jan; 350(5):482-92. PubMed ID: 14749457
[No Abstract] [Full Text] [Related]
14. Androgen deprivation therapy for prostate cancer.
Bahnson R
J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
[No Abstract] [Full Text] [Related]
15. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy.
Pinkawa M; Fischedick K; Piroth MD; Gagel B; Borchers H; Jakse G; Eble MJ
Urology; 2007 Jan; 69(1):129-33. PubMed ID: 17270634
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
Halland A; Jønler M; Pedersen KV
Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
[TBL] [Abstract][Full Text] [Related]
18. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
19. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
20. Intermittent hormonal therapy for prostate cancer.
da Silva FC
Curr Opin Urol; 2011 May; 21(3):248-51. PubMed ID: 21427583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]